跳至主要内容
临床试验/NCT00879008
NCT00879008已完成不适用

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe AECB

Bayer0 个研究点目标入组 345 人开始时间: 2009年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
345
主要终点
Effectiveness and tolerance of/to the different therapies

研究概览

简要总结

In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.

详细描述

The study design was slightly changed to adapt the target population. Due to these changes the study was restarted on 8th December 2009.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Acute exacerbation of chronic bronchitis from Anthonisen type I or II
  • FEV1 of < 50 %
  • Patient must be ensured in the statutory health insurance
  • Further contraindications of the prescribed pharmaceutical products must be considered

排除标准

  • Patients who change from one cohort to the other

研究组 & 干预措施

Group 1

干预措施: Moxifloxacin (Avelox, BAY12-8039) (Drug)

结局指标

主要结局

Effectiveness and tolerance of/to the different therapies

时间窗: within the first 14 days

Possible hospitalisation rate

时间窗: within the first 14 days

次要结局

未报告次要终点

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验